MMP9 and meningioma: Our results suggest that the dosage of MMPs in the sera of CNS tumor patients and the immunohistochemical evaluation of MMP-9 and its correlation with Ki-67 only in meningiomas, might provide clinicians additional objective information on intracranial neoplasms.